Further studies are necessary to validate the use of Gal-3 as a potential diagnostic biomarker, particularly in establishing cut-offs in prospective clinical trials as well as to determine its advantage over commonly used biomarkers of cardiovascular diseases, such as cardiospecific troponins. Here, LGALS3 is linked to cardiovascular disorder.